Combination efficacy looks similar to Kura’s, but adverse events with revumenib could raise concerns again.

Starglo reveals a surprisingly strong survival benefit in an EHA late-breaker.

The group's enthusiasm is backed by an academic trial of INB-100 in 10 AML patients.

As the dust settles on ASCO the weekend’s immediate winners and losers emerge.

A Car-T therapy to which Astra has rights has wowed in a solid tumour after others had disappointed.

The group is keeping faith with the novel target KLK2.

Tagrisso is a knockout on PFS, but only OS will show whether it should be given before patients progress.

The company’s pivotal trial is now set to start in the second half of 2025, from year-end 2024 previously.